EMEA-001864-PIP03-19

Table of contents

Key facts

Invented name
Takhzyro
Active substance
lanadelumab
Therapeutic area
Other
Decision number
P/0476/2020
PIP number
EMEA-001864-PIP03-19
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Prevention of attacks of Idiopathic non-histaminergic angioedema (INHA)
Route(s) of administration
Subcutaneous use
Contact for public enquiries
Shire Pharmaceuticals Ireland Limited (a Takeda company)
E-mail: medinfoEMEA@shire.com
Tel: +800 66838470
Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

Related content

Topics

How useful was this page?

Add your rating